ALS Biopharma Press Release
Doylestown, PA. August 21, 2014:
ALS Biopharma, LLC has been granted an exclusive license to Riluzole Prodrug technology originally developed by Fox Chase Chemical Diversity Center, Inc., for the treatment of ALS or any other indication.
Back to Press Releases